

APPROXIMATE VTE RISK IN CAUCASIANS WITH NO PERSONAL HISTORY OF VTE

Characteristic	Relative Risk	Absolute Risk (per year)
Individuals < 40 yrs of age	N/A	1 in 10,000
Individuals aged 41-75	N/A	1 in 1,000
Individuals >75 yrs of age	N/A	1 in 100
Family History of VTE	3-4 fold	1 in 2,500 (using <40 yr old abs. risk)
Heterozygous factor V Leiden	3-7 fold	1 in 2,000 (using <40 yr old abs. risk)
Homozygous factor V Leiden	80 fold	1 in 125 (using <40 yr old abs. risk)
Heterozygous prothrombin G20210A	2-3 fold	1 in 625 (using <40 yr old abs. risk)
Factor V Leiden + prothrombin G20210A	20 fold	1 in 500 (using <40 yr old abs. risk)
Heterozygous protein C deficiency	7-10 fold	1 in 1,250 (using <40 yr old abs. risk)
Heterozygous protein S deficiency	7-10 fold	1 in 1,250 (using <40 yr old abs. risk)
Heterozygous antithrombin deficiency	10-20 fold	1 in 625 (using <40 yr old abs. risk)
All women on oral contraceptives	2-6 fold	1 in 2,500
Women who are heterozygous factor V Leiden on oral contraceptives	35 fold	1 in 300
Women who are homozygous factor V Leiden on oral contraceptives	50-100 fold	1 in 150
Women who are heterozygous prothrombin G20210A on oral contraceptives	16 fold	1 in 600
All pregnant women	5 fold	1 in 1,000 – 1 in 2,000
Pregnant women who are heterozygous prothrombin G20210A	15 fold	1 in 600 – 1 in 700
Pregnant women who are heterozygous factor V Leiden	20-25 fold	1 in 400 – 1 in 500
Pregnant women who are heterozygous factor V Leiden and prothrombin G20210A	100 fold	1 in 100
All women on hormone replacement therapy	2-4 fold	1 in 300 – 1 in 400
Women on hormone replacement w/ heterozygous factor V Leiden	13-15 fold	1 in 70

References: Press, 2002; McGlennen, 2002; Kottke-Marchant, 2002; adapted from Varga, 2007